Screening of FDA-Approved Drugs for Treatment of Emerging Pathogens

Date
2016Journal
ACS Infectious DiseasesPublisher
American Chemical SocietyType
Article
Metadata
Show full item recordAbstract
The current outbreaks of Middle East Respiratory Syndrome (MERS) and Ebolavirus (EboV) have revealed a gap in the development and availability of drugs to treat these infections. To date, there are no approved treatments for patients infected with MERS coronavirus (MERS-CoV), a virus that continues to infect new patients and that has now spread from the Middle East to Asia. Despite a downward trend in the number of new EboV cases in West Africa, new infections are still occurring, and many patients continue to suffer from this illness. People infected with MERS and Ebola viruses receive only supportive care in hopes of recovery. Investigation into repurposing drugs approved by the FDA is gaining interest. To identify better treatment strategies, several groups have used drug screens to repurpose FDA-approved drugs as inhibitors of MERS-CoV and EboV.Keyword
Food and Drug Administration-approved drugsdrug screening
Drug Evaluation, Preclinical
Middle East Respiratory Syndrome Coronavirus
Ebolavirus
Identifier to cite or link to this item
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84969219474&doi=10.1021%2facsinfecdis.5b00089&partnerID=40&md5=b0f3732fc413098185e317dec8c4583f; http://hdl.handle.net/10713/12404ae974a485f413a2113503eed53cd6c53
10.1021/acsinfecdis.5b00089